Welcome to our dedicated page for Pro-Dex Colo news (Ticker: PDEX), a resource for investors and traders seeking the latest updates and insights on Pro-Dex Colo stock.
Pro-Dex Inc (PDEX) delivers precision-engineered medical devices and motion control systems for surgical and industrial applications. This news hub provides investors and industry professionals with authoritative updates on the company’s latest developments.
Access real-time announcements including product launches, financial results, and strategic partnerships. Our curated collection ensures you stay informed about PDEX’s innovations in torque-limiting surgical tools, multi-axis automation systems, and engineering services.
Key coverage areas include regulatory milestones, manufacturing expansions, and technology patents. All content is verified for accuracy and relevance to support informed decision-making.
Bookmark this page for streamlined access to Pro-Dex Inc’s evolving role in medical device innovation and industrial automation. Check regularly for updates directly impacting market positioning and technical advancements.
Pro-Dex (Nasdaq: PDEX) reported fiscal 2026 first quarter results for the period ended September 30, 2025. Net sales rose 24% to $18.5M, driven mainly by resumption of shipments of a next-generation handpiece to the company's largest customer. Gross margin fell 6 percentage points to 29% due to higher costs and tariffs. Operating income was $3.1M and net income was $4.68M ($1.40 diluted), which included $3.3M of unrealized investment gains. The company received $8.9M cash from the sale of Monogram shares and filed its Form 10-Q on October 30, 2025.
Pro-Dex (NasdaqCM: PDEX) issued a market clarification on October 16, 2025 to help avoid confusion between its Nasdaq-listed common stock and an unrelated crypto entity using the PDEX symbol. The company emphasized there is no relationship or affiliation with Polkadex and urged investors to verify whether research or trades referencing PDEX relate to Pro-Dex or to Polkadex.
Pro-Dex designs and manufactures autoclavable, battery-powered, and electric multi-function surgical drivers and shavers for orthopedic, thoracic, and maxocranial facial markets, and sells rotary air motors that represent a de minimis portion of revenue. Contact: Richard L. Van Kirk, CEO, (949) 769-3200.
Pro-Dex (NASDAQ:PDEX), a manufacturer of surgical drivers and shavers, reported its fiscal 2025 Q4 and full-year results. Annual net sales increased 24% to $66.6 million, driven by next-generation handpiece sales to their largest customer. Full-year net income surged to $9.0 million ($2.67 per diluted share), up from $2.1 million ($0.60 per diluted share) in fiscal 2024.
Q4 net sales grew 16% to $17.5 million, though gross margin declined from 27% to 20% due to unfavorable product mix and tariff costs. The company reported a strong backlog of $50.4 million as of June 30, 2025, and management expects continued revenue and operating income growth in fiscal 2026.
Pro-Dex (PDEX) reported strong financial results for Q2 FY2025. Net sales increased 33% to $16.8 million, driven by $3.1 million in shipments of next-generation orthopedic handpieces and $1.6 million increase in repair revenue from their largest customer.
Gross profit rose 81% to $5.1 million, with gross margin improving by 8 percentage points to 30%. Operating income surged 247% to $2.7 million, while net income reached $2.0 million ($0.61 per diluted share), up from $500,000 ($0.14 per diluted share) in Q2 FY2024.
For the six-month period, net sales grew 29% to $31.7 million, with net income of $4.5 million ($1.33 per diluted share), compared to a net loss of $115,000 in the prior year period. The company expects continued revenue growth in Q3 and Q4 due to ongoing production shipments of the next-generation handpiece.
Pro-Dex (NASDAQ:PDEX) reported strong financial results for Q1 FY2025. Net sales increased 25% to $14.9 million, driven by increased repairs and shipment of next-generation handpiece. Gross profit rose 41% with margin expanding to 35%. Operating income grew 64% to $3.0 million. Net income improved to $2.5 million ($0.75 per diluted share) from a net loss of $615,000 in the prior year. The company expects to ship production volumes of the new handpiece during second half of fiscal year.
Pro-Dex (NASDAQ:PDEX) reported strong financial results for Q4 and FY 2024. Q4 net sales increased 41% to $15.0 million, driven by a $3.4 million revenue boost from their largest customer. Q4 operating income rose 46% to $2.4 million. FY 2024 net sales grew 17% to $53.8 million, with operating income up 25% to $7.2 million. However, net income for FY 2024 decreased to $2.1 million ($0.60 per diluted share) from $7.1 million in FY 2023, primarily due to unrealized losses on marketable equity investments. The company highlighted successful growth despite transitioning to a multiple-facility operation and announced the hiring of a new Director of Operations to support future expansion.
Pro-Dex, Inc. reported strong fiscal 2024 third quarter and nine-month results with increases in net sales and operating income. However, net income declined due to unrealized losses on marketable equity investments. The company remains optimistic about future growth.
FAQ
What is the current stock price of Pro-Dex Colo (PDEX)?
What is the market cap of Pro-Dex Colo (PDEX)?
